Drug‑Free Diabetes Therapy: Implant Reduces Blood Glucose in Mice

Diabetes affects more than 830 million people worldwide, and conventional type 2 treatments such as insulin and GLP‑1 receptor agonists require careful dosing.

The experimental implant does not rely on insulin; instead, it removes glucose from the body without drugs, genes, or living cells.

The 3‑centimeter device contains a catalyst of gold flakes and platinum particles on a spongy graphite matrix. When powered, the catalyst converts glucose into gluconate, which the kidneys excrete, thereby lowering blood glucose levels.

In mouse studies, the implant normalized blood sugar within 60–90 minutes of activation, and after six weeks the treated mice lost up to 10 % of their body weight and exhibited reduced triglyceride levels.

The system operates automatically: a wearable glucose monitor sends readings to a smartphone, which switches the implant on when glucose is high and off when it returns to a safe range. The trial ran for two weeks in eight mice, and the catalyst remained functional for up to three months under the skin, though the overall device longevity is still unknown.

Human application faces challenges. Experts note that excessive gluconate excretion could disturb acid‑base balance, causing nausea or confusion, and may deplete electrolytes such as sodium and potassium. Scaling the device to handle the roughly 250 g of daily carbohydrate intake in humans—versus the 2 g consumed by mice—may require a larger implant or multiple units. Laboratory tests have shown that a larger prototype can clear nearly all glucose from about 5 L of fluid, approximating an adult’s blood volume, but not the full daily load.

Researchers plan to test the device in pigs and sheep before considering human trials. If proven safe and effective, the technology could offer an alternative to existing diabetes treatments and provide a new weight‑loss option for individuals regardless of diabetic status.

Source link